Unknown

Dataset Information

0

Not All EGFR Exon 20 Insertions Are Created Equal.

ABSTRACT:

SUBMITTER: Lin YT 

PROVIDER: S-EPMC8474363 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors.
| S-EPMC5596996 | biostudies-literature
Unknown Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions.
| S-EPMC8455549 | biostudies-literature
Unknown Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions.
| S-EPMC5932243 | biostudies-literature
Unknown Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung Cancer.
| S-EPMC8648093 | biostudies-literature
Unknown Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
| S-EPMC7400778 | biostudies-literature
Unknown Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC.
| S-EPMC6764748 | biostudies-literature
Unknown Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with <i>EGFR</i> Exon 20 Insertions.
| S-EPMC8127357 | biostudies-literature
Unknown EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
| S-EPMC3306520 | biostudies-literature
Unknown Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition.
| S-EPMC7792550 | biostudies-literature
Unknown Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions.
| S-EPMC8698942 | biostudies-literature